InVivo Therapeutics Announces Pricing of $15.0 Million Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of a public offering of 18,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 18,750,000 shares of common stock at a combined effective price to the public of $ 0.80 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering are expected to be approximately $15.0 million, before deducting the placement agent fees and offering expenses payable by InVivo Therapeutics.